Phase I Study of Rabusertib (LY2603618) in Combination with Gemcitabine in Patients with advanced/metastatic Solid Tumours.
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Gemcitabine (Primary) ; Rabusertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 08 Mar 2017 New trial record